JP2004527489A5 - - Google Patents

Download PDF

Info

Publication number
JP2004527489A5
JP2004527489A5 JP2002567272A JP2002567272A JP2004527489A5 JP 2004527489 A5 JP2004527489 A5 JP 2004527489A5 JP 2002567272 A JP2002567272 A JP 2002567272A JP 2002567272 A JP2002567272 A JP 2002567272A JP 2004527489 A5 JP2004527489 A5 JP 2004527489A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
oral pharmaceutical
composition according
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527489A (ja
Filing date
Publication date
Priority claimed from GBGB0104752.1A external-priority patent/GB0104752D0/en
Application filed filed Critical
Publication of JP2004527489A publication Critical patent/JP2004527489A/ja
Publication of JP2004527489A5 publication Critical patent/JP2004527489A5/ja
Pending legal-status Critical Current

Links

JP2002567272A 2001-02-27 2002-02-25 フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 Pending JP2004527489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
PCT/SE2002/000327 WO2002067904A1 (en) 2001-02-27 2002-02-25 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Publications (2)

Publication Number Publication Date
JP2004527489A JP2004527489A (ja) 2004-09-09
JP2004527489A5 true JP2004527489A5 (enExample) 2005-12-22

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567272A Pending JP2004527489A (ja) 2001-02-27 2002-02-25 フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物

Country Status (14)

Country Link
US (1) US20040138231A1 (enExample)
EP (1) EP1365746A1 (enExample)
JP (1) JP2004527489A (enExample)
KR (1) KR20040011469A (enExample)
CN (1) CN1533268A (enExample)
BR (1) BR0206960A (enExample)
CA (1) CA2435815A1 (enExample)
GB (1) GB0104752D0 (enExample)
IL (1) IL156830A0 (enExample)
MX (1) MXPA03006746A (enExample)
NO (1) NO20033782L (enExample)
NZ (1) NZ527080A (enExample)
WO (1) WO2002067904A1 (enExample)
ZA (1) ZA200305386B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
EP2278957A2 (en) * 2008-04-15 2011-02-02 Schering Corporation Oral pharmaceutical compositions in a solid dispersion comprising preferably posaconazole and hpmcas
EP2346495B2 (en) * 2008-10-07 2023-05-24 Kudos Pharmaceuticals Limited Pharmaceutical formulation 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
CA3038312A1 (en) 2016-09-30 2018-04-05 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (enExample) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DE69428707T2 (de) * 1993-08-20 2002-07-11 Nippon Shinyaku Co., Ltd. Im magen verbleibende zubereitung, quellender formkörper und herstellungsverfahren
CN1133634C (zh) * 1998-05-02 2004-01-07 阿斯特拉曾尼卡有限公司 抑制因子Xa的杂环衍生物
JP5159012B2 (ja) * 1999-12-23 2013-03-06 メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド 不良溶解性の薬物に対する改良された医薬組成物

Similar Documents

Publication Publication Date Title
JP2012509263A5 (enExample)
RU2002123350A (ru) Дипептиднитрильные ингибиторы катепсина К
JP2008520742A5 (enExample)
JP2010501478A5 (enExample)
JP2010511631A5 (enExample)
JP2004512328A5 (enExample)
JP2003531118A5 (enExample)
EP2397476A3 (en) Indole derivative having PGD2 receptor antagonist activity
JP2006182786A5 (enExample)
TWI334866B (en) Novel physiologically active substances
MY136034A (en) New medicaments for the treatment of chronic obstructive pulmonary disease
JP2008517926A5 (enExample)
JP2005531584A5 (enExample)
JP2006515838A5 (enExample)
JP2004524316A5 (enExample)
JP2010530376A5 (enExample)
JP2007091758A5 (enExample)
JP2007522135A5 (enExample)
CY1107203T1 (el) Χρηση αναστολεων της il - 18 για τη θεραπεια και/ή την προληψη καρδιακης νοσου
CN115803328A (zh) 哌嗪-2,3-二酮衍生物及其在医药上的应用
JP2006501306A5 (enExample)
JP2008513510A5 (enExample)
SE0402762D0 (sv) Indazole sulphonamide derivatives
RU2008143232A (ru) Новый класс ингибиторов гистондеацетилаз
JP2008516004A5 (enExample)